For the quarter ending 2026-03-31, HOTH had -$3,008,870 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Stock-based compensation | - | 968,000 | 219,929 |
| Stock-based professional fees | - | 166,575 | 55,525 |
| Lease costs | - | -1,110 | 3,245 |
| Net loss | 7,088,648 | -4,105,801 | -5,675,312 |
| Lease costs | 851,526 | 0 | -850,500 |
| Unrealized loss of crypto assets | - | -25,305 | - |
| Realized loss on crypto assets | 44,165 | - | - |
| Prepaid expenses and other current assets | - | - | 155,221 |
| Prepaid expenses | 30,158 | 356,643 | - |
| Change in fair value of investment in joint ventures | - | - | 0 |
| Accounts payable and accrued expenses | -210,660 | 655,781 | -459,527 |
| Net cash used in operating activities | 4,603,000 | -2,492,672 | -5,160,861 |
| Purchase of crypto assets | - | 300,000 | - |
| Proceeds from sale of crypto assets | 147,202 | - | - |
| Proceeds from exercise of warrants | - | 0 | 5,625,000 |
| Net cash provided by investing activities | 447,202 | -300,000 | - |
| Taxes paid related to net share settlement of equity award | - | 376,000 | - |
| Proceeds from issuance of common stock, net of offering costs | -2,810,072 | 2,003,491 | 1,508,065 |
| Net cash provided by financing activities | -8,059,072 | 1,627,491 | 7,133,065 |
| Net (decrease) increase in cash and cash equivalents | -3,008,870 | -1,165,181 | 1,972,204 |
| Effect of exchange rate changes on cash and cash equivalents | -387 | 1,965 | - |
| Cash and cash equivalents - beginning of period | 7,847,911 | 7,038,923 | - |
| Cash and cash equivalents - end of period | 4,047,198 | 7,847,911 | - |
Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. (HOTH)